Throughout the course of my career, I have been involved in a wide range of portfolio decisions and continue to be involved in them today. Over the years, it has been observed that despite cultural differences, pharma teams face similar problems.
By Christoph Oldenburg, Dr Markus Thunecke and Dr John Herrmann
While CAR-T have already demonstrated convincing efficacy in a specific setting, the jury is still out on whether they are a âgame-changerâ for oncology and can justify current valuations and investor interest.
Collectively rare diseases affect millions of people worldwide, but the number of people with any one condition is very small. Finding a cure is difficult as the market is not large enough to justify a big investment in drug development.
Magnetic Resonance Imaging (MRI) can be used to provide quantitative measurements in the form of imaging biomarkers. These measurements have attractive characteristics: non-invasive, can provide organ and lesion localisation of morphology, physiology and metabolism and can be repeated over time.
18 January 2016: Innova Biosciences , specialist provider of bioconjugation products and services, today announced the launch of Thunder-Link® PLUS, a new and improved version of the original Thunder-Link kit.
Enzo Life Sciences continues to expand its ELISA portfolio. A leading manufacturer of high quality ELISAs, Enzo continues to invest in developing immunoassays with the launch of their new VEGF ELISA Kit.
The United States Patent and Trademark Office has issued a patent to Cayman Chemical and the University of Michigan claiming novel reagents used for screening small-molecule chemical libraries for new drug leads.